Influx Healthtech Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Influx Healthtech Ltd trades at ₹282, in a confirmed uptrend and 54 weeks into that stage. That is +23.3% against its own 200-day average. It sits at 86% of a 52-week range of ₹169 to ₹301. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.

Today the stock is in a confirmed uptrend — week 54 of stage 2, confirmed. At ₹282 it trades +23.3% versus its 200-day average and sits at 86% of its 52-week range (₹169–₹301).

Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +110% while the NIFTY 500 moved −1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 93rd percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Influx Healthtech Ltd trades at 32.7× P/E, at the pricey end of its own range (93rd percentile). Its long-run median P/E is 25.8×, measured across 1.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 32.7× is at the pricey end of its own range (93rd percentile), against a long-run median of 25.8× measured over 1.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved +20.4% against a +78.1% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Influx Healthtech Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

65.0/100 — rank 41 of 43 in Pharma - Formulators · 50% evidence confidence · provisional, ranked below fully-evidenced peers

Influx Healthtech Ltd scores 65.0 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 41. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 19.1 + 20.8 + 10 + 15.1 = 65. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Influx Healthtech Ltd reported ₹80.0 Cr of revenue in the Mar 26 quarter, +40.4% year on year. That is the 2nd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹147 Cr. The last four reported quarters add to ₹252 Cr.

Influx Healthtech Ltd reported ₹80.0 Cr of revenue in the Mar 26 quarter, +40.4% year on year. That is the 2nd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹147 Cr. The last four reported quarters add to ₹252 Cr.

FY26 revenue came in at ₹147 Cr (+40.0% on the year). The latest quarter (Mar 26) printed ₹80.0 Cr, +40.4% year on year — the 2nd consecutive quarter of year-over-year growth.

→ Revenue grew — did margins hold as it scaled? Next: 19.0% this quarter (−1.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Influx Healthtech Ltd's operating margin is 19.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 11.0% to 20.0%. The current quarter sits inside that band.

Influx Healthtech Ltd's operating margin is 19.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 11.0% to 20.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 19.0%, −1.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 11.0%–20.0%, and FY26's 20.0% is the top of that band — a record year.

Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

→ Margins slipped — did that reach the bottom line? Next: profit +37.5% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Influx Healthtech Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +37.5% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹21.0 Cr. That is 13.8% of the quarter's revenue.

Influx Healthtech Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +37.5% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹21.0 Cr. That is 13.8% of the quarter's revenue.

Mar 26 profit was ₹11.0 Cr, +37.5% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹21.0 Cr (+61.5%).

→ Profit rose — but did the cash follow? Next: 44% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 44% of Influx Healthtech Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹4.0 Cr of operating cash against ₹21.0 Cr of profit. After ₹16.0 Cr of capital spending, ₹−12.0 Cr was left as free cash.

FY26: operating cash of ₹4.0 Cr against reported profit of ₹21.0 Cr, leaving free cash of ₹−12.0 Cr after ₹16.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 44% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 44%: the cash cycle stretched 81 days between FY22 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 81 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 71-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Influx Healthtech Ltd's cash conversion cycle runs 71 days in FY26, up from −10 days in FY22. Capital spending ran ₹34.0 Cr over the last 3 years. At FY26 sales of ₹147 Cr each day of that cycle holds about ₹0.4 Cr, so roughly ₹29.0 Cr sits inside the business at any moment.

FY26: debtors at 84 days, inventory at 67 days — roughly 2.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 71 days, looser than FY22's −10.

The full loop: cash goes out to suppliers and production on day 0; stock waits 67 days to sell; customers pay about 84 days after that; and suppliers themselves are paid at 80 days — netting out to the 71-day cycle.

In money terms: at FY26 sales of ₹147 Cr, each day of the cycle holds about ₹0.4 Cr — so the 71-day loop keeps roughly ₹29.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹34.0 Cr over the last 3 fiscal years against ₹9.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹3.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 40% and the ROIC − WACC spread is +16.2 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Influx Healthtech Ltd earns a ROCE of 40% in FY26. Return on invested capital clears the cost of that capital by +16.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.3% net margin on 1.19× asset turns.

FY26 ROCE is 40%.

Why the return is what it is — the wiring (FY26): 14.3% net margin × 1.19× asset turns × 1.23× balance-sheet leverage ≈ 20.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 28.2% − 12.0% = a +16.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Influx Healthtech Ltd carries ₹0.0 Cr of borrowings against ₹101 Cr of equity in FY26, a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Capital spending ran ₹34.0 Cr across the last 3 of those years.

FY26: borrowings of ₹0.0 Cr against equity of ₹101 Cr — a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr while capital spending ran ₹34.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Influx Healthtech Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — .

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Influx Healthtech Ltd: the Z-score reads 15.04. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 15.04 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 15.04.

Frequently asked questions